GrowthCraft

Startup Funding

Investor Money vs. Go-To-Market First: How Startup Founders Should Decide on One of the First Real Decisions They Face

Investor Money vs. Go-To-Market First:

Investor Money vs. Go-To-Market First: How Startup Founders Should Decide on One of the First Real Decisions They Face

How Startup Founders Should
Decide on One of the First Real Decisions They Face

For first-time and early-stage founders, few decisions feel as consequential as this one:
Do we raise investor money early, or do we focus on building a go-to-market strategy and grow from customer revenue?

The startup ecosystem often frames this choice as binary, but in reality, it’s a strategic continuum. Many iconic companies raised venture capital early. Just as many built meaningful traction, revenue, and leverage before taking a dollar of outside funding.

Understanding the trade-offs matters because this decision shapes how you build your product, how you hire, how fast you move, and how much control you retain.

This article breaks down both paths using Y Combinator and General Catalyst, two of the most influential voices in startup formation and scaling,as references to provide well-established thinking. The goal is not to tell you which path is “right,” but to help you choose the one that best fits your market, product, and personal risk tolerance.

Two Fundamentally Different Startup Philosophies

The Investor-First Philosophy

This approach prioritizes raising capital early to move fast, hire aggressively, and scale before competitors. Capital is treated as fuel to buy speed, talent, and market share.

This model is common in:

  • Winner-take-most markets
  • Platform or marketplace businesses
  • Capital-intensive or regulated industries

The Go-To-Market-First Philosophy

A GTM-first strategy focuses on selling early, learning from customers, and funding growth through revenue. Capital efficiency and product-market fit come before scale.

This model is common in:

  • B2B SaaS and services-enabled software
  • Niche or vertical solutions
  • Founder-led sales motions

Most startups eventually blend these approaches, but the order matters more than founders often realize.

The Case for Raising Investor Money Early

1. Speed Can Be a Competitive Advantage

In certain markets, speed matters more than efficiency. Venture capital allows startups to:

  • Hire ahead of revenue
  • Invest heavily in product and marketing
  • Expand geographically or vertically faster

If network effects or data advantages compound over time, moving slowly can mean losing permanently.

General Catalyst often emphasizes that capital is a tool to accelerate proven momentum, particularly when markets reward scale. Their approach frames capital not as validation, but as leverage.

2. Access to Talent, Networks, and Pattern Recognition

Strong investors bring more than capital. They bring:

  • Customer and partner introductions
  • Help recruiting senior leaders
  • Experience from similar companies at similar stages

Your capital investment partner should describe its role as supporting founders “beyond capital,” particularly in go-to-market execution, hiring, and operational scale. For founders without deep operating networks, this can significantly shorten learning curves.

3. Long Runways Enable Bigger Bets

Some products simply cannot be built on early revenue alone. Deep tech, infrastructure, healthcare, and hardware often require years of development before monetization.

Venture capital allows founders to:

  • Absorb early losses
  • Invest in long-term R&D
  • Build defensible technology before revenue scales

In these cases, GTM-first is often unrealistic.

4. Signaling and Credibility

While not always rational, market perception matters. Funding from well-known firms can:

  • Increase trust with enterprise buyers
  • Attract stronger candidates
  • Create inbound interest from partners

This signaling effect can materially change how quickly doors open.

The Downsides of Raising Investor Money

1. Dilution and Control Trade-Offs

Every round trades ownership for capital. Over time, dilution compounds. More importantly, governance can change:

  • Boards gain influence
  • Growth expectations increase
  • Strategic optionality narrows

Founders often underestimate how quickly their company’s priorities can shift after funding.

2. Pressure to Scale Before You’re Ready

One of the most common failure modes in venture-backed startups is premature scaling. Capital can mask:

  • Weak product-market fit
  • Inefficient acquisition channels
  • Poor retention

Y Combinator has repeatedly warned founders that growth without real customer pull is fragile. Scaling too early often locks in the wrong product or GTM motion.

3. Fundraising Becomes a Job

Raising capital is time-consuming and mentally draining. Paul Graham, co-founder of Y Combinator, famously points out that fundraising rewards founders who run structured, parallel processes and understand investor psychology.

That time almost always comes at the expense of:

  • Talking to customers
  • Improving the product
  • Closing actual deals

4. Exit Expectations Change the Game

Venture capital comes with expectations of large outcomes. That can:

  • Push companies toward high-risk growth strategies
  • Eliminate viable “small but profitable” outcomes
  • Force exits that don’t align with founder goals

Not every founder wants to build a billion-dollar company, and that’s okay.

The Case for a Go-To-Market-First Strategy

1. Customers Are the Best Validation

A GTM-first approach forces founders to answer the hardest questions early:

  • Who is the buyer?
  • What problem do they pay to solve?
  • How long does it take to close?
  • Why do they stay?

A lot of consulting firms repeatedly emphasize talking to users and doing “things that don’t scale” early. Those conversations shape better products than pitch decks ever will.

2. Capital Efficiency Builds Stronger Businesses

When revenue matters, discipline follows. GTM-first companies learn:

  • True customer acquisition costs
  • Realistic lifetime value
  • Sustainable pricing

This often leads to healthier companies that can endure downturns and truly adapt to market shifts, not just survive them.

3. Founders Retain Control and Optionality

Bootstrapping or delaying funding preserves:

  • Equity ownership
  • Strategic freedom
  • Pace control

Revenue gives founders leverage. When you eventually raise, you do so on better terms and from a position of strength…not desperation.

4. GTM Muscle Compounds

Selling early builds institutional knowledge:

  • Messaging that resonates
  • Repeatable sales motions
  • Onboarding and retention insights

These capabilities compound and dramatically increase valuation if and when you raise capital.

The Risks of a GTM-First Approach

1. Slower Scaling

Without capital, growth is naturally constrained. This can be dangerous in fast-moving markets or where competitors are heavily funded.

2. Founder Burnout

Early GTM-first startups often rely heavily on founders to sell, support, and build simultaneously. Without relief, this can limit long-term scalability.

3. Missed Market Windows

In markets driven by network effects or rapid consolidation, moving too slowly can mean losing relevance entirely.

A Practical Decision Framework for Founders

Ask yourself:

Market Dynamics

  • Is this a winner-take-most market?
  • Do network effects or data moats matter?

Capital Intensity

  • Can early customers fund development?
  • Are there regulatory or infrastructure costs?

Sales Motion

  • Can founders sell this product themselves?
  • Is there early willingness to pay?

Personal Goals

  • Do you value control or speed more?
  • Are you building a company or swinging for a category?

Your answers point clearly toward one strategy or a hybrid.

The Hybrid Path: GTM First, Capital Second

Many of the strongest startups today validate through GTM first, then raise capital to scale what’s already working.

General Catalyst frequently backs companies that demonstrate:

  • Clear customer demand
  • Repeatable GTM motions
  • Strong unit economics

This approach reduces risk for both founders and investors and aligns incentives around sustainable growth.

Final Thoughts

Raising investor money is not a badge of honor. Bootstrapping is not a limitation. They are tools.

Y Combinator’s guidance consistently reminds founders that customers matter more than capital. General Catalyst’s perspective reinforces that capital is most powerful when applied to proven momentum.

The best founders understand both…and choose intentionally.

If you can sell early, do it. If you must raise to build, do it wisely. And if you can combine the two, you give yourself the greatest leverage of all.

Investor Money vs. Go-To-Market First: Read More »

a dna helix made out of dolla rbills

4 Answers to Key SBIR Questions in 2025

4 Answers to Key SBIR Questions in 2025

a dna helix made out of dolla rbills

There have been a lot of reports in the news recently about changes in Federal grant policies. Even those who are only casual tourists to this world will have heard about pauses in grant reviews at the various funding agencies, potentially drastic cuts in funding levels, and other general rumblings that the sky is about to fall.
The policies of the new administration vis-à-vis R&D funding are still being finalized, instituted—and, in some cases, litigated.  But enough information has now emerged that we can start to draw some reasonable inferences about what all this means for the ~ $4.5B in SBIR/STTR grants that is disbursed every year and that is such an important source of non-dilutive funding for high tech startups.  And the answer is…not much.

That’s right.  Carry on, nothing to see here, folks.

At AwardIT, we have been getting regularly contacted over the past month or so, with varying levels of panic, about potential changes in SBIR/STTR policies. We thought it might help to gather up a few of the questions and try to answer them as clearly and concisely as possible. 

Question 1: I’ve heard that the NIH is going to limit Indirect Costs to 15%?  Isn’t that a big deal?

Answer: for Institutes of Higher Education (IHE), it sure is. They have become accustomed to getting >50% (in some cases, up to ~90%) on top of the dollars that directly support the research program being funded at their Institution.  That is going to be a wrench to do without—which is why they are challenging the ruling in the courts.

We are grant consultants, not lawyers, but FWIW our view is that this is a legal battle the IHEs are unlikely to win.  The executive branch really does have Constitutional authority in these matters. But no matter how that ruling shakes out, it seems clear that this change in IC rates is intended ONLY for IHE grants.  We’ve read the NIH Guidance on the recent change in IC policy NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates (we do stuff like this so you don’t have to).  The CFRs cited in that Guidance, such as CF 75.414, make it clear that IHEs and nonprofits are regulated under a different budgetary policy than SBs and for-profit entities.  

The above is, more or less, the same policy for the other agencies with the largest SBIR/STTR budgets (NSF, DOE, DOD)

Takeaway: Indirect Cost rates for SBIR grants, as far as we can tell right now, can be expected to remain in the 20%-40% range, where they have always been.

Question 2: is overall funding support for SBIR/STTR going down?  

Answer: for Institutes of Higher Education (IHE), it sure is. They have become accustomed to getting >50% (in some cases, up to ~90%) on top of the dollars that directly support the research program being funded at their Institution.  That is going to be a wrench to do without—which is why they are challenging the ruling in the courts.

We are grant consultants, not lawyers, but FWIW our view is that this is a legal battle the IHEs are unlikely to win.  The executive branch really does have Constitutional authority in these matters. But no matter how that ruling shakes out, it seems clear that this change in IC rates is intended ONLY for IHE grants.  We’ve read the NIH Guidance on the recent change in IC policy NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates (we do stuff like this so you don’t have to).  The CFRs cited in that Guidance, such as CF 75.414, make it clear that IHEs and nonprofits are regulated under a different budgetary policy than SBs and for-profit entities.  

The above is, more or less, the same policy for the other agencies with the largest SBIR/STTR budgets (NSF, DOE, DOD)

Takeaway: Indirect Cost rates for SBIR grants, as far as we can tell right now, can be expected to remain in the 20%-40% range, where they have always been.

Question 3: review/funding of my grant has been delayed.  How long will I have to wait?

Answer: Applicants at all of the big 4 agencies have experienced some delay in processing of grants since January.  This is not that unusual during a change in Administration.  It’s been a little more pronounced (and announced) this time around, but the reality is a lot of the focus for the internal audit is on academic grant funding, not SBIR/STTR grants.  As fas as SBIR/STTR goes: the latest feedback from NIH  is that study sections are being convened, reviews are being issued, happy grants are getting funded.  Similarly, at DOD SBIR grants have been largely unaffected (Pentagon says small business programs not part of grant funding pause)

The exception is NSF, which is currently undergoing a significant transformation in its overall structure. Budget cuts and personnel layoffs have already taken place at the agency, and more are likely to follow. In the latest twist, on April 24 the NSF director Sethuraman Panchanathan announced he would resign (Trump’s first-term pick to run the National Science Foundation quits: ‘I have done all I can’). 

So much change was sure to have an impact and the agency’s April 16 announcement that grant review would be paused was perhaps not a huge surprise.  But again, SBIR/STTR seems to be largely sheltered so far: Project Pitches and applications for the upcoming July 2 NSF SBIR/STTR application deadline are still being accepted.  Most importantly, as of this writing, the NSF budget for SBIR/STTR grants remains where it was (see above).

Takeaway: if you have a grant application in the queue for Spring 2025, expect some amount of slowdown in getting your review or for funding to flow.  This is especially true at NSF.  But overall things are still moving forward.

Question 4: You are telling me that things are OK for now. But can’t SBIR grants be abolished by Executive Order?  Could they just vanish overnight?

Answer: In a word–no. The SBIR program was established by an Act of Congress over 40 years ago. It has been renewed, with bipartisan support, every 3 years since that time. Our representatives may not be able to agree on much, but they seem to consistently agree on maintaining the SBIR/STTR program, and Federal law cannot be changed just with the famous “stroke of a pen”.  

In summary: there is no doubt that US R&D funding priorities have changed with the advent of a new administration. What else is new? The answer is to stay flexible and shift grant strategy in response to the new realities. We at AwardIT have been grant consultants for a long time and have seen this happen more than once. Despite alarmist reports, it does not appear that any of the recent news will have much impact on Federal agencies overall SBIR/STTR spending or review processes. Onward!

Want to learn more?  Reach out to AwardIT at https://awardit.net/ or email me at neal@awardit.net.  It’s a world of smart ideas, we look forward to learning more about yours.

4 Answers to Key SBIR Questions in 2025 Read More »

Scroll to Top